Nexien BioPharma, Inc.

As of March 31, 2025, Nexien BioPharma, Inc. carries a market capitalization of 636,949.76, placing it among publicly traded companies globally. Its enterprise value stands at 1.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Nexien BioPharma, Inc. has 70.77M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Nexien BioPharma, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -83.32, indicating conservative leverage, while an interest coverage ratio of -1.70 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -1,667.99, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on October 6, 2026, Nexien BioPharma, Inc.'s stock has declined approximately 99.17% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended March 31, 2025, Nexien BioPharma, Inc. generated - - in revenue and converted that into -188,082.00 in net income, yielding earnings per share of 0.00. EBITDA reached -118,322.00, while operating income came in at -118,322.00.

As of March 31, 2025, Nexien BioPharma, Inc. holds 8,285.00 in cash and equivalents against 375,375.00 in total debt, resulting in a net debt position of 367,090.00. Total book value stands at -450,516.00, with working capital of -450,516.00 providing operational flexibility.

Nexien BioPharma, Inc. produced -61,782.00 in operating cash flow over the twelve months ended March 31, 2025.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -9.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.42, meaning Nexien BioPharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nexien BioPharma, Inc.'s most recent stock split took place on November 30, 2017 with a 6:1 split ratio.

As of March 31, 2025, Nexien BioPharma, Inc. has an Altman Z-Score of -2,077.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.